Literature DB >> 25442220

Editorial: cell movement.

S Detchokul1, A G Frauman.   

Abstract

UNLABELLED: Cell movement is a fundamental process of normal cellular physiology and pathophysiology. Abnormal regulation of cell migration is a common denominator of many medical disorders, including cancer metastasis, autoimmune disease and inflammation. Increased interest in the targeting of cell migration and invasion, which has potential for therapeutic intervention in many diseases are behind this special themed issue. Thus, the focus of this issue is centred on the control of cellular cytoskeletal dynamics and cellular or tissue microenvironment sensors. Novel therapeutic opportunities targeting regulation of cell migration are discussed including the emerging roles of tetraspanins, phosphoinositides, transient receptor potential cation channels, stromal interaction molecules and calcium release-activated calcium modulators. Better understanding of these regulatory factors will hopefully bring greater attention to strategically targeting aberrant cell migration, which has many therapeutic implications for common human diseases. LINKED ARTICLES: This article is part of a themed section on Cytoskeleton, Extracellular Matrix, Cell Migration, Wound Healing and Related Topics. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-24
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2014        PMID: 25442220      PMCID: PMC4290696          DOI: 10.1111/bph.12849

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

Review 1.  Natalizumab (Tysabri).

Authors:  D T Selewski; G V Shah; B M Segal; P A Rajdev; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-05       Impact factor: 3.825

Review 2.  Cell mechanics and the cytoskeleton.

Authors:  Daniel A Fletcher; R Dyche Mullins
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

Review 3.  Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.

Authors:  Kazuhiro Ito; Gaetano Caramori; Ian M Adcock
Journal:  J Pharmacol Exp Ther       Date:  2006-10-04       Impact factor: 4.030

Review 4.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 5.  TRP channels and STIM/ORAI proteins: sensors and effectors of cancer and stroma cell migration.

Authors:  N Nielsen; O Lindemann; A Schwab
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

6.  NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.

Authors:  Ta-Jen Liu; Dimpy Koul; Tiffany LaFortune; Ningyi Tiao; Rui Jun Shen; Sauveur-Michel Maira; Carlos Garcia-Echevrria; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

Review 7.  GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.

Authors:  Ines M Macias-Perez; Ian W Flinn
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 8.  Movers and shakers: cell cytoskeleton in cancer metastasis.

Authors:  C M Fife; J A McCarroll; M Kavallaris
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

9.  Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.

Authors:  Fen Yang; Xiao-Jun Qian; Wei Qin; Rong Deng; Xiao-Qi Wu; Juan Qin; Gong-Kan Feng; Xiao-Feng Zhu
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

Review 10.  Targeting Rho-GTPases in immune cell migration and inflammation.

Authors:  Maté Biro; Marcia A Munoz; Wolfgang Weninger
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.